Drug Profile
SRM 003
Alternative Names: SHP-613; SRM003; VascugelLatest Information Update: 15 Jan 2019
Price :
$50
*
At a glance
- Originator Massachusetts Institute of Technology
- Developer Shire
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Peripheral arterial disorders; Peripheral vascular disorders
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 17 Jul 2014 Discontinued - Phase-II for Peripheral vascular disorders in USA (Implant)
- 23 Jul 2013 Shire restarts enrolment in two phase II trials for Peripheral vascular disorders (haemodialysis access) in USA (NCT01806545, NCT01806584)